Pooled analysis of included studies revealed that first-line ADCs for HER2-positive advanced GC achieved integrated efficacy outcomes: ORR 67% (95% CI: 53%–82%), median OS 19.67 months (95% CI: 15.79-23.55), and median PFS 10.57 months (95% CI: 6.37-14.77). Here, ERBB2 is linked to gastric cancer.